Hovione, a globally-integrated pharmaceutical Contract Development and Manufacturing Organization (CDMO), has opened 89 Twin Rivers, a new 31,000-square-foot facility at its East Windsor, N.J. campus that doubles the company's U.S. spray drying capacity and further reinforces Hovione´s global leadership in this technology platform.
Approximately 70% of small-molecule drug candidates exhibit poor aqueous solubility, limiting bioavailability and slowing development. Hovione addresses this persistent formulation challenge by turning poorly soluble drug ingredients into more bioavailable forms using amorphous solid dispersions through its specialized spray drying platform. The company also draws upon more than 25 years of specialized manufacturing expertise in spray drying featuring formulation science, predictive and model-based development tools, scale-up expertise and drug product manufacturing to help customers address this challenge.
The opening of the 89 Twin Rivers facility completes Hovione's current $100 million U.S. investment cycle and represents the first major milestone in the next phase of evolution of its integrated East Windsor, N.J., campus. Over the coming decade, Hovione’s vision is to continue growing its U.S. operations, further strengthening the site as a next-generation pharmaceutical development and manufacturing hub. The new facility will employ approximately 80 people.
“Opening 89 Twin Rivers is more than a capacity expansion. It marks the next chapter in Hovione’s legacy of more than two decades in the U.S.,” said Marco Gil and Antonio Almeida, Co-Chief Executive Officers of Hovione. “This investment enables us to meet growing demand while further reinforcing our global leadership in pharmaceutical spray drying. Equally important, this technology sits within an integrated offering that extends from drug substance through drug product, giving customers a more direct and resilient path from early development to commercial. This is how we help them address poor solubility, one of the industry’s most persistent development challenges, and bring complex medicines to patients faster.”